CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

Apr 27, 2021

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Apr 21, 2021

CohBar to Present at the Mitochondria-Targeted Drug Development Summit

Apr 14, 2021

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

Mar 30, 2021

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Mar 29, 2021

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

Mar 16, 2021

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases

Mar 16, 2021

CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 12, 2021

CohBar to Present at the 33rd Annual ROTH Conference

Mar 2, 2021

CohBar to Present at the H.C. Wainwright Global Life Sciences Conference

Feb 25, 2021